Sprout Pharmaceuticals, Inc.

RALEIGH, NC · Founded 2011 · Biotech · Acquired

Flibanserin, an oral pharmaceutical therapeutic for hypoactive sexual desire disorder (HSDD) in women

Claim this profile

Follows are private to you and power your alerts

Updated · sproutpharmaceuticals.com

Sector
Biotech
Headquarters
RALEIGH, NC
Founded
2011
Latest Form D
$50M, Jun 2015
Total capital
$81.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$81.7M
5 Form D · last Jun 2015
137 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
15
25 pending · first 2016
Rank in peer group#112 of 1449

Capital timeline

2012201320142015FEDERAL ↑EQUITY ↓Cumulative $81.7M2nd Form D$17.6M3rd Form D$4.8M4th Form D$4.3M5th Form D$50M
2012201320142015FEDERAL ↑EQUITY ↓Cumulative $81.7M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$50M
  • Private capital raisedForm D · SEC · 4th filing$4.3M
  • Private capital raisedForm D · SEC · 3rd filing$4.8M
  • Private capital raisedForm D · SEC · 2nd filing$17.6M
  • Private capital raisedForm D · SEC · 1st filing$5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#112 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anne S. TomalinExecutive OfficerNamed in SEC Form D filings
  • Anthony Robert WildDirectorNamed in SEC Form D filings
  • Braxton Robert GoodrichDirectorNamed in SEC Form D filings
  • Cynthia S. WhiteheadExecutive OfficerNamed in SEC Form D filings
  • Douglas W. EckertExecutive Officer, DirectorNamed in SEC Form D filings
  • Fred S. PrudenExecutive OfficerNamed in SEC Form D filings
Show all 17 people
  • James S PrudenExecutive OfficerNamed in SEC Form D filings
  • James Robert SymonsExecutive OfficerNamed in SEC Form D filings
  • Josephine S. TorrenteExecutive OfficerNamed in SEC Form D filings
  • Matthew S. PetzoldExecutive OfficerNamed in SEC Form D filings
  • Michael Robert FordDirectorNamed in SEC Form D filings
  • Richard Robert DeSchutterDirectorNamed in SEC Form D filings
  • Rich S. FrancoExecutive OfficerNamed in SEC Form D filings
  • Robert W. DahlDirectorNamed in SEC Form D filings
  • Robert S. WhiteheadExecutive Officer, DirectorNamed in SEC Form D filings
  • Trygve Robert MikkelsenDirectorNamed in SEC Form D filings
  • W. Robert DahlDirectorNamed in SEC Form D filings

What it has protected

USPTO · 15 granted of 40
  • PendingTreating Sexual Desire Disorders With FlibanserinUSPTOApplication 17351854
  • GrantedTreating Sexual Desire Disorders With FlibanserinUSPTOUS 11,058,683
  • PendingUse Of Flibanserin In The Treatment Of ObesityUSPTOApplication 17101961
Show all 40 patent records
  • Treating Sexual Desire Disorders With FlibanserinOct 7, 2021 · Application 17351854Pending
  • Treating Sexual Desire Disorders With FlibanserinJul 13, 2021 · US 11,058,683Granted
  • Use Of Flibanserin In The Treatment Of ObesityMar 11, 2021 · Application 17101961Pending
  • Use Of Flibanserin In The Treatment Of ObesityDec 29, 2020 · US 10,874,668Granted
  • Treatment Of Vasomotor SymptomsAug 13, 2020 · Application 16810273Pending
  • Treating Sexual Desire Disorders With FlibanserinJun 9, 2020 · US 10,675,280Granted
  • Treatment of Vasomotor SymptomsMar 24, 2020 · US 10,596,170Granted
  • Use of Flibanserin in the Treatment of ObesityJul 2, 2019 · US 10,335,407Granted
  • Treating Sexual Desire Disorders with FlibanserinJun 4, 2019 · US 10,307,420Granted
  • Treatment of Vasomotor SymptomsJan 1, 2019 · US 10,166,230Granted
  • Treating Sexual Desire Disorders with FlibanserinOct 16, 2018 · US 10,098,876Granted
  • Flibanserin for the Treatment of Urinary Incontinence and Related DiseasesJun 26, 2018 · US 10,004,731Granted
  • Treatment of Vasomotor SymptomsApr 24, 2018 · US 9,949,969Granted
  • Treating Sexual Desire Disorders with FlibanserinOct 10, 2017 · US 9,782,403Granted
  • Flibanserin for the Treatment of Urinary Incontinence and Related DiseasesSep 19, 2017 · US 9,763,936Granted
  • Use of Flibanserin in the Treatment of ObesityAug 15, 2017 · US 9,730,927Granted
  • SaltsJan 17, 2017 · US 9,546,141Granted
  • Treating Sexual Desire Disorders with FlibanserinOct 18, 2016 · US 9,468,639Granted
  • Use Of A Polymorph Of Flibanserin For Treating DiseaseApr 7, 2016 · Application 14876235Pending
  • Pharmaceutical compositions containing flibanserinApr 7, 2016 · Application 14867779Pending
  • Use of Flibanserin for the Treatment of Post-Menopausal Sexual Desire DisordersDec 31, 2015 · Application 14702125Pending
  • Use of flibanserin for the treatment of pre-menopausal sexual desire disordersDec 24, 2015 · Application 14665083Pending
  • Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor AffinityDec 24, 2015 · Application 14690981Pending
  • Pharmaceutical Compositions for the Treatment of Sexual Disorders IINov 12, 2015 · Application 14656877Pending
  • Use of Flibanserin for the Treatment of Sexual Disorders in FemalesAug 27, 2015 · Application 14583292Pending
  • Formulations Of FlibanserinAug 13, 2015 · Application 14570467Pending
  • Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual DisordersJun 11, 2015 · Application 14519374Pending
  • Method Of Using Flibanserin For NeuroprotectionFeb 26, 2015 · Application 14319420Pending
  • Use of Flibanserin for the Treatment of Post-Menopausal Sexual Desire DisordersFeb 19, 2015 · Application 14313291Pending
  • Treating Sexual Desire Disorders with FlibanserinJan 8, 2015 · Application 14269373Pending
  • Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor AffinityJan 8, 2015 · Application 14273126Pending
  • Use Of A Polymorph Of Flibanserin For Treating DiseaseJan 1, 2015 · Application 14269420Pending
  • Pharmaceutical compositions containing flibanserinJan 1, 2015 · Application 14269468Pending
  • Use of flibanserin for the treatment of pre-menopausal sexual desire disordersNov 6, 2014 · Application 14196431Pending
  • Treating Sexual Desire Disorders with FlibanserinFeb 27, 2014 · Application 13920354Pending
  • Method Of Using Flibanserin For NeuroprotectionFeb 13, 2014 · Application 13906766Pending
  • Use Of A Polymorph Of Flibanserin For Treating DiseaseJan 30, 2014 · Application 13905709Pending
  • Pharmaceutical compositions containing flibanserinJan 9, 2014 · Application 13863566Pending
  • Treatment of Vasomotor SymptomsJan 2, 2014 · Application 13847683Pending
  • Use of flibanserin for the treatment of pre-menopausal sexual desire disordersAug 29, 2013 · Application 13675164Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .